EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 197 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma 2026 ESMO Breast Cancer Award Recipient Announced Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type MOST POPULAR Popular Fitness Instructor Encourages Others to Maintain Routine Check Ups After... February 9, 2021 Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line... May 22, 2023 Five Questions with…Fred. April 14, 2022 FDA Approves Darolutamide Tablets for Metastatic Hormone-Sensitive Prostate Cancer August 16, 2022 Load more HOT NEWS Prising open the trap: Getting to grips with targeted cancer drug... Growing the Cancer Research Pipeline by Expanding Opportunities Reused, Reheated Cooking Oil May Trigger Breast Cancer Progression, Metastasis Wales: 4 in 10 with possible cancer symptoms didn’t contact GP
